Literature DB >> 34162524

Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease.

Bermingham B1, Rueschhoff A2, Ratti G2, Nesmith A3, Goodwin D3, Gray S1, Flume P1, Solomon G M3, Cohen L2, Garcia B4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34162524     DOI： 10.1016/j.jcf.2021.05.009

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN： 1569-1993            Impact factor:   5.482


× No keyword cloud information.
  1 in total

1.  Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study.

Authors:  Vincenzo Carnovale; Paola Iacotucci; Vito Terlizzi; Carmela Colangelo; Lorenza Ferrillo; Angela Pepe; Michela Francalanci; Giovanni Taccetti; Serena Buonaurio; Assunta Celardo; Laura Salvadori; Giovanni Marsicovetere; Michele D'Andria; Nicola Ferrara; Donatello Salvatore
Journal:  J Clin Med       Date:  2022-02-16       Impact factor: 4.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.